NEW YORK — Teva Pharmaceutical Industries Ltd. and Impax Laboratories Inc. have released minocycline HCl extended-release tablets, an acne medication, in 65 mg and 115 mg dosages.

Teva’s minocycline HCl ER tablets

The minocycline products are generic versions of Solodyn (minocycline HCl ER tablets, 65 mg and 115 mg) from Ortho Dermatologics, a unit of Valeant Pharmaceuticals International Inc. Impax’s minocycline product is an authorized generic.

An oral antibiotic, minocycline HCl ER tablets are indicated for the treatment of non-nodular inflammatory lesions (pimples and red bumps) for moderate to severe acne in people 12 and older. The medication isn’t effective for acne that is not red-looking (non-inflammatory), such as blackheads and whiteheads.

“The launch of these two strengths of our generic version of Solodyn brings an effective, affordable treatment option to patients who are managing this condition, and marks our ninth generic medicine in the tetracycline category,” stated Brendan O’Grady, executive vice president and head of North America commercial at Teva.

U.S. sales of minocycline HCl ER tablets (65 mg and 115 mg) totaled approximately $148 million for the 12 months through December, according to IQVIA market data reported by Teva and Impax.